Skip to main content
. 2020 Jan 15;16:155–160. doi: 10.1016/j.omtm.2019.12.017

Figure 1.

Figure 1

Categories of Current DC Trials Where the Drug Includes a DC as a Biologic Component of Treatment

A total of 120 trials met the criteria. Most of them (n = 113) were for malignancies, further defined as non-hematological malignancies (n = 95), and hematological malignancies (n = 18). Trials for non-malignant indications include autoimmune disorders (n = 5) and chronic viral infections (n = 2).